Labcorp Holdings (LH) Cash & Equivalents (2009 - 2026)

Labcorp Holdings (LH) has 18 years of Cash & Equivalents data on file, last reported at $981.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 165.59% year-over-year to $981.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $981.1 million (up 165.59% YoY) and the FY2025 annual result came in at $532.3 million, down 64.95% from the prior year.
• Cash & Equivalents rose to $981.1 million in Q1 2026 per LH's latest filing, from $532.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.9 billion in Q2 2023, with the low at $99.3 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $773.6 million, with a median of $598.1 million recorded in 2025.
• Year-over-year, Cash & Equivalents plunged 86.27% in 2024 and soared 272.0% in 2025.
• Labcorp Holdings' Cash & Equivalents stood at $320.6 million in 2022, then soared by 67.44% to $536.8 million in 2023, then surged by 182.92% to $1.5 billion in 2024, then tumbled by 64.95% to $532.3 million in 2025, then surged by 84.31% to $981.1 million in 2026.
• Business Quant data shows LH's Cash & Equivalents at $981.1 million in Q1 2026, $532.3 million in Q4 2025, and $598.1 million in Q3 2025.